PSNL - Personalis Inc Stock Price, Fair Value and News

$5.75+0.49 (+9.32%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PSNL Price Action

Last 7 days

50.5%

Last 30 days

66.2%

Last 90 days

0.2%

Trailing 12 Months

280.8%

PSNL RSI Chart

PSNL Valuation

Market Cap

406.2M

Price/Earnings (Trailing)

-4.44

Price/Sales (Trailing)

4.64

EV/EBITDA

-4.13

Price/Free Cashflow

-7.43

PSNL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PSNL Fundamentals

PSNL Revenue

Revenue (TTM)

87.5M

Rev. Growth (Yr)

40.89%

Rev. Growth (Qtr)

13.86%

PSNL Earnings

Earnings (TTM)

-91.4M

Earnings Growth (Yr)

-34.34%

Earnings Growth (Qtr)

-205.34%

PSNL Profitability

Operating Margin

31.41%

EBT Margin

-104.50%

Return on Equity

-54.83%

Return on Assets

-38.12%

Free Cashflow Yield

-13.45%

PSNL Investor Care

Shares Dilution (1Y)

44.09%

Diluted EPS (TTM)

-1.68

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	74.1M	80.0M	87.5M	0
2023	68.7M	67.1M	70.5M	73.5M
2022	79.8M	76.4M	69.0M	65.0M
2021	80.4M	82.5M	85.0M	85.5M
2020	70.3M	74.0M	76.6M	78.6M
2019	47.7M	54.7M	60.2M	65.2M
2018	16.5M	23.6M	30.7M	37.8M
2017	0	0	0	9.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Personalis Inc

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.

CEO	Mr. Christopher M. Hall
WEBSITE	personalis.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	395

Personalis Inc Frequently Asked Questions

What is the ticker symbol for Personalis Inc? What does PSNL stand for in stocks?

PSNL is the stock ticker symbol of Personalis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Personalis Inc (PSNL)?

As of Fri Dec 20 2024, market cap of Personalis Inc is 406.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PSNL stock?

You can check PSNL's fair value in chart for subscribers.

Is Personalis Inc a good stock to buy?

The fair value guage provides a quick view whether PSNL is over valued or under valued. Whether Personalis Inc is cheap or expensive depends on the assumptions which impact Personalis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSNL.

What is Personalis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, PSNL's PE ratio (Price to Earnings) is -4.44 and Price to Sales (PS) ratio is 4.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSNL PE ratio will change depending on the future growth rate expectations of investors.